Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kith Pradhan

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Experimental Hematology|February 2, 2026
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesisBianca Rivera-Peña, Samarpana Chakraborty, Yang Shi, et al.
The Journal of Biological Chemistry|December 3, 2016
Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal CancerTushar D Bhagat, Yiyu Zou, Shizheng Huang, et al.
Blood Advances|December 6, 2019
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemiasAshwin Sridharan, Carolina D Schinke, George Georgiev, et al.
Elife|October 31, 2019
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblastsTushar D Bhagat, Dagny Von Ahrens, Meelad Dawlaty, et al.
JCI Insight|July 27, 2018
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanomaOrsi Giricz, Yongkai Mo, Kimberly B Dahlman, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Elife|August 30, 2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutationsGaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, et al.
Blood|August 15, 2018
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesUrvi A Shah, Elaine Y Chung, Orsi Giricz, et al.
The Journal of Clinical Investigation|September 26, 2018
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cellsAditi Shastri, Gaurav Choudhary, Margarida Teixeira, et al.
Nature Communications|May 13, 2026
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesisSrinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Experimental Hematology|February 2, 2026
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesisBianca Rivera-Peña, Samarpana Chakraborty, Yang Shi, et al.
The Journal of Biological Chemistry|December 3, 2016
Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal CancerTushar D Bhagat, Yiyu Zou, Shizheng Huang, et al.
Blood Advances|December 6, 2019
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemiasAshwin Sridharan, Carolina D Schinke, George Georgiev, et al.
Elife|October 31, 2019
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblastsTushar D Bhagat, Dagny Von Ahrens, Meelad Dawlaty, et al.
JCI Insight|July 27, 2018
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanomaOrsi Giricz, Yongkai Mo, Kimberly B Dahlman, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Elife|August 30, 2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutationsGaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, et al.
Blood|August 15, 2018
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesUrvi A Shah, Elaine Y Chung, Orsi Giricz, et al.
The Journal of Clinical Investigation|September 26, 2018
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cellsAditi Shastri, Gaurav Choudhary, Margarida Teixeira, et al.
Nature Communications|May 13, 2026
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesisSrinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, et al.
Pageof 9